ACRS Market Cap History
Below is a table of the ACRS market cap history going back to 10/7/2015:

Date ACRS Market Cap

Also see: ACRS Shares Outstanding History
and ACRS YTD Return
ACRS Historical Market Cap:
+25.03% CAGR
ACRS Historical Market Cap: +25.03% CAGR

Mouse over chart for data details
10/7/2015 ...10/31/2022
Aclaris Therapeutics is a biopharmaceutical company that develops drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes Zunsemetinib, which is for the indication of rheumatoid arthritis (moderate to severe), psoriatic arthritis (moderate to severe), and hidradenitis suppurativa (moderate to severe); ATI-1777, which is for the indication of atopic dermatitis (moderate to severe); ATI-2138, which is for the indication of T cell-mediated autoimmune diseases; Gut-Biased Program, which is for the indication of inflammatory bowel disease; and ATI-2231, which is for the indication of metastatic breast cancer and pancreatic cancer. We show 30 historical shares outstanding datapoints in our ACRS shares outstanding history coverage, used to compute ACRS market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ACRS market cap history over the course of time is important for investors interested in comparing ACRS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ACRS versus a peer is one thing; comparing ACRS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ACRS can fluctuate over the course of history. With this page we aim to empower investors researching ACRS by allowing them to research the ACRS market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree ACRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aclaris Therapeutics (ACRS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ACRV Market Cap History
ACRX Market Cap History
ACST Market Cap History
ACXP Market Cap History
ADGI Market Cap History
ADIL Market Cap History
ADMA Market Cap History
ADMP Market Cap History
ADMS Market Cap History
ADPT Market Cap History
More Healthcare companies »


ACRS Market Cap History | | Copyright © 2017 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.